COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Multicenter Open Label Phase II Study of Pomalidomide and Cyclophosphamide and Dexamethasone in Relapse/Refractory Multiple Myeloma Patients Who Were First Treated Within the IFM/DFCI 2009 Trial (PCD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02244125
Recruitment Status : Unknown
Verified April 2018 by Institut Curie.
Recruitment status was:  Active, not recruiting
First Posted : September 18, 2014
Last Update Posted : April 6, 2018
Intergroupe Francophone du Myelome
Celgene Corporation
Information provided by (Responsible Party):
Institut Curie